LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”) announces that a class action lawsuit has been filed on behalf of investors who purchased Alcobra Ltd. (“Alcobra” or the “Company”) (NASDAQ: ADHD) securities between August 13, 2015 and January 17, 2016, inclusive (the “Class Period”). Alcobra investors have until April 18, 2017 to file a lead plaintiff motion.
Investors suffering losses on their Alcobra investments are encouraged to contact Lesley Portnoy of GPM to discuss their legal rights in this class action at 310-201-9150 or by email to firstname.lastname@example.org.
Alcobra is a biopharmaceutical company that focuses on the development and commercialization of oral drug candidates.
On January 17, 2017, Alcobra disclosed that the Company's attention deficit hyperactivity disorder drug, Metadoxine Extended Release (“MDX”), did not satisfy its primary endpoint in a Phase 3 trial.
On this news, Alcobra stock fell over 50%, to close at just $0.94 per share on January 17, 2017.
The complaint filed in this class action lawsuit alleges that the Company issued materially misleading statements concerning the Company's second Phase III study for MDX in adults with attention deficit hyperactivity disorder ("ADHD").
If you purchased shares of Alcobra during the Class Period you may move the Court no later than April 18, 2017 to ask the Court to appoint you as lead plaintiff if you meet certain legal requirements. To be a member of the Class you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the Class. If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley Portnoy, Esquire, of GPM, 1925 Century Park East, Suite 2100, Los Angeles California 90067 at 310-201-9150, Toll-Free at 888-773-9224, by email to email@example.com, or visit our website at http://glancylaw.com. If you inquire by email please include your mailing address, telephone number and number of shares purchased.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.